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Fig. 1. One-way, valved, atrial septal patch. (From Luluaga IT, Yosifides de Luluagi I. Cierre gradual de 
las communicaciones interauriculares con severa hypertensión pulmonar: presentación de dos casos operados. 
Arch Fund Roux-Ocefa 1969;3:101-4; published with the permission of Roux-Ocefa Foundation.) 
5. Williams rJV, Salamonsen RF, Snell G, et al. Preliminary 
experience udth inhaled nitric oxide for acute pulmonary 
hypertension after heart transplantation. J Heart Lung 
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Reply to the Editor: 
The observations described by George, Black, and Boscoe 
are interesting. They appear to corroborate the beneficial 
effects of nitric oxide that my colleagues and I described-- 
reduction of acutely increased pulmonary vascular resistance 
after cardiopulmonary b pass (CPB) during implantation of 
a left ventricular assist system (LVAS). 
We would like to comment specifically on their question 
about the 30-minute delay that we observed before the 
beneficial effect of nitric oxide administration became 
apparent. 
We agree that nitric oxide administration is followed by 
a rapid (i.e., <5 minutes) decrease in pulmonary vascular 
resistance. In fact, we observed a rapid decrease in 
pulmonary artery pressure. However, inasmuch as our 
patient was supported by CPB, right ventricular preload 
was reduced, so that the LVAS could not fill completely 
and LVAS output was thus unable to increase signifi- 
cantly. However, peak LVAS filling volume rapidly in- 
creased, which onfirmed that the patient's hemodynamic 
status had improved. After almost 30 minutes the situa- 
tion appeared to be stable, with no further decrease in 
pulmonary vascular esistance or increase in pump filling 
rate. We completely agree that this beneficial effect was a 
combination of nitric oxide administration, which reduces 
right ventricular afterload, and possible recovery of right 
ventricular ~unction as a result of prolonged CPB. This 
was precisely what we hoped to achieve by waiting 30 
minutes with the patient supported by complete CPB. 
Nevertheless, when CPB support was progressively re- 
duced, so that right ventricular preload increased, the 
beneficial effects of a reduced right ventricular afterload 
became vident, as indicated by satisfactory LVAS output. 
Regarding the problem of demonstrating the beneficial 
effects of nitric oxide administration, we took great care to 
maintain an appropriate nitric oxide concentration when 
the patient was transported to the intensive care unit or 
when the cylinder was changed. 
Finally, George, Black, and Boscoe expressed concern 
regarding the poor prognosis of bridge to transplantation 
with an implantable LVAS alone in patients requiring 
nitric oxide administration. We still believe that this 
therapeutic approach allowed us to reduce the increase in 
pulmonary vascular esistance resulting from CPB, thus 
affording the possibility for progressive right ventricular 
recovery. This apparently was the case with our patient, 
who undelwent successful transplantation 3 months after 
LVAS implantation. 
Paul Michael Mertes, MD 
Service de Chirurgie Cardiaque et
Transplantations Cardio-Thoraciques 
CHU Nancy-Barbois 
Rue du Morvan 
Vandoeuvre les Nancy, France 
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Valved atrial septal patch 
To the Editor: 
I read with interest he article of Ad and associates 1 
from the Beilinson and Tel-Aviv Medieal Centers on their 
experimental results achieved with a one-way, valved, 
atrial septal patch. The pateh was to be used in the 
management of postoperative right heart failure in pa- 
tients with congenital heart defects characterized by 
hypoplastic right ventricle or pulmonary hypertension. At 
the end of the article they suggested that a prospective 
clinical trial should be done. 
In 1967, Luluaga and Yosifides de Luluaga performed 
a similar operation to treat atrial septal defect with severe 
pulmonary hypertension i two patients, with uneventful 
recovery. The photograph of the patch (Fig. 1) is similar to 
that used in dogs by Ad and assoeiates. 
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I am delighted to call attention to a scientific ontribu- 
tion made 25 years ago. 
Ricardo M. Leyro-Diaz, MD 
Division of Cardiac Surgery 
Hospital Churruca 
Uspallata 3400 
1437, Buenos Aires, Argentina 
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Reply to the Editor." 
We thank Dr. Leyro-Diaz for bringing to our attention 
the report by Drs. Luluaga and Yosifides de Luluaga on 
their clinical experience. Their work, in which they used a 
device closely resembling ours, is very important. Such an 
experience with two patients with an atrial septal defect 
and pulmonary hypertension contributes greatly to the 
establishment of this surgical concept of decompressing 
the right ventricle through an interatrial communication 
to reduce the risk of postoperative right heart failure. We 
congratulate Drs. Luinaga and Yosifides de Luluaga for 
this early work. We wish their work had been published in 
the English medical literature, so that it would have been 
available to English-speaking physicians. 
A prospective clinical trial comprising 15 patients has 
already been performed and will be published in Trm 
JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY. In 
this trial, patients for whom the one-way, valved, atrial septal 
patch was deemed suitable were divided into three groups: 
group 1 comprised patients with hypoplastic right ventricle, 
small tricuspid valve, and severe pulmonic stenosis or atresia; 
group 2 comprised patients with high pulmonary vascular 
resistance resulting from a large left-to-right shunt from an 
atrial or ventricular septal defect; and group 3 comprised 
patients with intraoperative acute right heart failure devel- 
oping after complete repair of their congenital malforma- 
tion. The right heart failure was resistant to maximal phar- 
macologic treatment, and the device was used as a last resort 
to wean the patients from cardiopulmonary b pass. 
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Monofilament polypropylene sutures in aortic 
valve replacement 
To the Editor." 
We read with interest a recent article from Gott and 
associates ~ reporting extremely low rates of thromboem- 
bolism after aortic root replacement. The authors pec- 
ulated in their discussion section that the lower inci- 
dence of thromboembolism may h ve been related to 
the fact that the valve sutures, pledgets, knots, and 
much of the valve sewing ring are excluded from the 
bloodstream in a composite graft but remain exposed in 
isolated valve replacement. We agree with this state- 
ment and believe that suture material may increase the 
likelihood of morbid complications such as thromboem- 
bolism and prosthetic valve endocarditis (PVE) after 
cardiac operations. Despite major advances, such as the 
development of antimicrobial prophylaxis, better pre- 
operative preparation of the skin, improved surgical 
techniques, early, aggressive treatment of wound infec- 
tion, and prevention of low-output syndrome after 
operation, PVE continues to complicate the course of 
2% to 4% of patients after cardiac valve replacement. 2 
We report here our experiences related to PVE after 
aortic valve replacement (AVR). 
In the early phase of cardiac surgery at our hospital, 
polyfilament suture material was used in AVR. We ana- 
lyzed the cases of a series of 283 patients operated on 
from 1972 to 1984, In this series, all prostheses basically 
had interrupted single sutures without pledgets. Eleven of 
the patients (4.1%) had infective PVE or periprosthetic 
leakage and had to undergo reoperation. At reoperation, 
swelling and untying of the polyfilament sutures and 
penetration of infection deeply into the aortic wall along 
the sutures, causing annular abscesses, were encountered. 
This experience l d us to change the suture material, and 
since the mid-1980s we have routinely used 2-0 Prolene 
sutures (Ethicon, Inc., Somerville, N.J.) in all AVRs, 
inserting 30 to 40 interrupted single sutures without 
pledgets. We have now evaluated our 583 AVR opera- 
tions from 1985 to 1994, and to date only one patient with 
infective PVE and periprosthetic leakage has needed 
reoperation, a rate of 0.1%. 
The suture material used in cardiac valve replacements 
in general varies between monofilament and multifila- 
ment types. In a study on the effect of suture material 
on the development of vascular infection, 102 Staphylo- 
coccus aureus bacteria were injected intravenously after 
aortotomy closure with various materials. 3 The study 
indicated that monofilament, nonabsorbable sutures 
were less likely to be associated with suture line infec- 
tion. Polyfilament material was found to have a dis- 
tinctly increased bacterial affinity relative to monofila- 
ment. 4 Our experience supports this finding. We 
conclude that single interrupted 2-0 Prolene sutures are 
a safe choice for AVR. 
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